KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage and grade. It exits in both secreted and membrane-associated forms, with ...

Circulating tumor DNA (ctDNA) — genetic material shed from tumors into the bloodstream — may help risk-stratify patients with ...

The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic subtype component, including pure histologic subtypes and variants which have ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant ...

For oncologists, seeing more young patients also raises the question of what happens after treatment, and this prompted the ...

Kura Oncology (KURA) announced new preliminary data from its farnesyl transferase inhibitor, FTI, programs – darlifarnib and tipifarnib – ...

The state-of-the-workforce report identifies challenges in cancer care access across the US, particularly in rural areas.

(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...

Investing.com -- Kura Oncology Inc (NASDAQ:KURA) stock rose 4.7% in Monday premarket trading following the company’s presentation of encouraging clinical data for its farnesyl transferase inhibitor ...

Dr. Hyatt “Tracy” DeGreen carries on his father’s legacy at Lancaster Cancer Center, offering compassionate, patient-first ...